JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Scope & Guideline

Transforming Knowledge into Therapeutic Solutions

Introduction

Explore the comprehensive scope of JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0022-3565
PublisherAMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1945 to 2024
AbbreviationJ PHARMACOL EXP THER / J. Pharmacol. Exp. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995

Aims and Scopes

The Journal of Pharmacology and Experimental Therapeutics (JPET) aims to advance the understanding of pharmacological principles and experimental therapeutics through comprehensive research articles. The journal focuses on the intersection of pharmacology and therapeutics, providing a platform for innovative studies that bridge basic science and clinical applications.
  1. Pharmacological Mechanisms:
    Research exploring the mechanisms of drug action at various biological targets, including receptor interactions, signaling pathways, and metabolic processes.
  2. Therapeutic Applications:
    Studies investigating the efficacy and safety of therapeutic agents in various disease models, emphasizing clinical relevance and translational potential.
  3. Drug Development and Delivery:
    Research focused on novel drug formulations, delivery systems, and technologies aimed at improving the pharmacokinetic and pharmacodynamic profiles of therapeutics.
  4. Neuroscience and Behavior:
    Papers examining the effects of pharmacological agents on neurological function and behavior, particularly in models of pain, addiction, and neurodegenerative diseases.
  5. Toxicology and Safety Assessment:
    Studies evaluating the safety profiles of drugs and their metabolites, including toxicity mechanisms and the impact of environmental factors.
  6. Pharmacogenomics and Personalized Medicine:
    Research addressing the genetic and molecular basis of individual responses to drugs, aiming to optimize therapeutic strategies through personalized approaches.
The Journal of Pharmacology and Experimental Therapeutics is currently witnessing several emerging themes that reflect the evolving landscape of pharmacological research. These trends highlight the journal's responsiveness to contemporary challenges in therapeutics and drug development.
  1. Nanomedicine and Drug Delivery Systems:
    There is a growing trend towards the exploration of nanotechnology in drug delivery, with research focusing on enhancing the efficacy and targeting of therapeutics using nanoparticle systems.
  2. Cannabis and Cannabinoid Research:
    An increased focus on the therapeutic potential of cannabinoids in various medical conditions, including pain management and neuroprotection, is evident in recent publications.
  3. Gene Therapy and Biologics:
    Research into gene therapy, including the use of RNA-based therapeutics and monoclonal antibodies, has gained traction, reflecting advancements in biopharmaceuticals.
  4. Chronic Pain and Opioid Alternatives:
    There is a significant emphasis on identifying non-opioid alternatives for pain management, addressing the opioid crisis through innovative pharmacological strategies.
  5. Translational Pharmacology and Precision Medicine:
    Emerging studies are increasingly focusing on translational pharmacology, emphasizing the integration of pharmacogenomics to tailor therapies to individual patient profiles.
  6. Microbiome and Pharmacology:
    Research exploring the interactions between the microbiome and pharmacological agents is becoming more prominent, highlighting its implications for drug metabolism and therapeutic outcomes.

Declining or Waning

While the Journal of Pharmacology and Experimental Therapeutics continues to thrive in many areas, certain themes have been observed to decline in prominence over recent years. This could reflect shifting research priorities or emerging trends that overshadow previous areas of focus.
  1. Traditional Medicinal Approaches:
    Research focusing on classical herbal or traditional medicinal practices appears to have waned, as more emphasis is placed on molecular and mechanistic studies.
  2. Single-Agent Pharmacotherapy:
    The interest in studies solely focused on single-agent pharmacotherapy is declining in favor of combination therapies and polypharmacy approaches that consider multi-target strategies.
  3. Basic Pharmacokinetic Studies:
    There is a noticeable reduction in the publication of basic pharmacokinetic studies, with an increasing preference for more complex modeling approaches and real-world evidence.
  4. Animal Models of Drug Interaction:
    Research centered exclusively on animal models for drug-drug interactions has decreased, likely due to the emerging focus on human-based studies and advanced computational models.
  5. In vitro Studies without Clinical Relevance:
    Papers reporting in vitro findings without clear translational implications or clinical relevance are less frequently accepted, reflecting a shift towards applied research.

Similar Journals

Advances in Pharmacological and Pharmaceutical Sciences

Empowering Global Collaboration in Pharmacology.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Elevating Knowledge in Medicine and Drug Innovation
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

Current Molecular Pharmacology

Exploring Innovations in Drug Discovery
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Illuminating the Complexities of Drug Mechanisms
Publisher: SPRINGERISSN: 0028-1298Frequency: 12 issues/year

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

Physiology and Pharmacology

Exploring the frontiers of biological systems and drug action.
Publisher: IRANIAN SOC PHYSIOLOGY & PHARMACOLOGYISSN: 2476-5236Frequency: 4 issues/year

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

BIOCHEMICAL PHARMACOLOGY

Transforming pharmaceutical applications with biochemical knowledge.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0006-2952Frequency: 12 issues/year

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

Journal of Pharmacological Sciences

Connecting researchers to drive pharmaceutical breakthroughs.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Bridging Science and Practice in Pharmacology and Toxicology
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Drug Target Insights

Illuminating Pathways in Drug Targeting and Development.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

ANTI-CANCER DRUGS

Leading the Charge in Cancer Drug Development
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.